SPARC announces submission of IND Application for SBO-154 to USFDA
The IND application supports the next phase of development of SBO-154
The IND application supports the next phase of development of SBO-154
These results represent critical milestones for Philogen, as Fibromun has the potential to become second product to successfully complete multinational clinical trials with registration potential
SPARC to receive 55% equity in Tiller Therapeutics
The product will be marketed by Dr. Reddy's
He recently served as Senior Vice President of the API business at Shilpa Pharma Life Sciences for over 3 years
Before joining Gland, Loomba was associated with Shalina Labs, Harman Finochem, Aurobindo Pharma, Sun Pharmaceuticals and Ranabaxy Laboratories.
Mungara has over 25+ years of experience in the supply chain domain
Bromfenac Ophthalmic Solution 0.075% (RLD BromSite) had estimated annual sales of USD 15 million in the U.S.
Subscribe To Our Newsletter & Stay Updated